Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 5, Number 1—February 1999

The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals

Robert J. Rubin, Catherine A. Harrington, Anna Poon, Kimberly Dietrich, Jeremy A. Greene, and Adil Moiduddin
Author affiliations: The Lewin Group, Fairfax, Virginia, USA

Main Article

Table 6

Incidence, length of stay, costs, and deaths of Staphylococcus aureus infections by source of infection and degree of resistance

Source of infection Incidence Direct medical cost
($M) Per patient
($) Deaths
Total (%)
Nosocomial 6,300 181.0 28,800 640 10
Community 7,250 254.5 5,300 760 11
Pneumonia 1,500 51.7 34,900 380 25
Non-pneumonia 5,750 202.8 35,400 380 7
MRSAa 2,780 94.5 34,000 590 21
MSSAb 10,770 339.4 31,500 810 8

aMethicillin-resistant strains of S. aureus.
bMethicillin-sensitive strains of S. aureus.

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.